Novo stays on generics market
Novo Nordisk will not leave it to others to make money off of generic copies of their insulin products – they want to get in on the action themselves. The Danish company and an analyst both dismiss the notion that dedicated generics manufacturers will emerge.
Lone Andersen, lone.andersen@jp.dk
The pressure on European health budgets is so great that a relatively large market for generic or older version of insulin products is bound to emerge.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
